header logo image


Page 39«..1020..38394041..5060..»

Archive for the ‘Arthritis’ Category

Rheumatoid Arthritis Treatment Market To Witness A Considerable CAGR Growth Through The Forecast Period 2017-2027 – Info Street Wire

Monday, December 30th, 2019

According to a new market study, the Rheumatoid Arthritis Treatment Market is projected to reach a value of ~US$XX in 2019 and grow at a CAGR of ~XX% over the forecast period 2017-2027. The presented study ponders over the micro and macro-economic factors that are likely to influence the growth prospects of the Rheumatoid Arthritis Treatment Marketover the assessment period.

The market report throws light on the current trends, market drivers, growth opportunities, and restraints that are likely to influence the dynamics of the Rheumatoid Arthritis Treatment Market on a global scale. The Five Force and SWOT analysis included in the report provides a fair idea of how the different players in the Rheumatoid Arthritis Treatment Market are adapting to the evolving market landscape.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.futuremarketinsights.co/reports/sample/REP-GB-3119

Analytical insights enclosed in the report:

The report splits the Rheumatoid Arthritis Treatment Marketinto different market segments including, region, end-use, and application.

The report provides an in-depth analysis of the current trends that are expected to impact the business strategies of key market players operating in the market. Further, the report offers valuable insights related to the promotional, marketing, pricing, and sales strategies of the established companies in the Rheumatoid Arthritis Treatment Market. The market share, growth prospects, and product portfolio of each market player are evaluated in the report along with relevant tables and figures.

The study aims to address the following doubts related to the Rheumatoid Arthritis Treatment Market:

Get Access To TOC Covering 200+ Topics athttps://www.futuremarketinsights.co/toc/REP-GB-3119

key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customized Report As Per Your Requirements athttps://www.futuremarketinsights.co/customization-available/REP-GB-3119

Why Opt for FMI?

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

Future Market Insights

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

T (UK): + 44 (0) 20 7692 8790

This post was originally published on Info Street Wire

Follow this link:
Rheumatoid Arthritis Treatment Market To Witness A Considerable CAGR Growth Through The Forecast Period 2017-2027 - Info Street Wire

Read More...

Systemic Idiopathic Juvenile Arthritis Treatment Market By Production, Manufacturer, Revenue Analysis And Forecast To 2029 – Bulletin Line

Monday, December 30th, 2019

Systemic Idiopathic Juvenile Arthritis Treatment Market (2018) Report Provides an in-depth summary of Systemic Idiopathic Juvenile Arthritis Treatment Market Status as well as Product Specification, Technology Development, and Key Manufacturers. The Report Gives Detail Analysis on Market concern Like Systemic Idiopathic Juvenile Arthritis Treatment Market share, CAGR Status, Market demand and up to date Market Trends with key Market segments.

The latest report about the Systemic Idiopathic Juvenile Arthritis Treatment market provides a detailed evaluation of the business vertical in question, alongside a brief overview of the industry segments. An exceptionally workable estimation of the present industry scenario has been delivered in the study, and the Systemic Idiopathic Juvenile Arthritis Treatment market size with regards to the revenue and volume have also been mentioned. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2534385&source=atm

Leading manufacturers of Systemic Idiopathic Juvenile Arthritis Treatment Market:

Alteogen Inc.Bristol-Myers Squibb CompanyEpirus Biopharmaceuticals, Inc.Johnson & JohnsonMomenta Pharmaceuticals, Inc.Mycenax Biotech Inc.Novartis AGOncobiologics, Inc.

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAdalimumab BiosimilarCanakinumabGolimumabTocilizumab BiosimilarOthers

Segment by ApplicationClinicHospitalOthers

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2534385&source=atm

Scope of The Systemic Idiopathic Juvenile Arthritis Treatment Market Report:

This research report for Systemic Idiopathic Juvenile Arthritis Treatment Market explores different topics such as product scope, product market by end users or application, product market by region, the market size for the specific product Type, sales and revenue by region forecast the Market size for various segments. The Report provides detailed information regarding the Major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Systemic Idiopathic Juvenile Arthritis Treatment market. The Systemic Idiopathic Juvenile Arthritis Treatment Market Report analyzes opportunities in the overall Systemic Idiopathic Juvenile Arthritis Treatment market for stakeholders by identifying the high-growth segments.

A detailed overview of the geographical and competitive sphere of the Systemic Idiopathic Juvenile Arthritis Treatment market:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2534385&licType=S&source=atm

Table of Content of The Report

Chapter 1- Systemic Idiopathic Juvenile Arthritis Treatment Industry Overview:

1.1 Definition of Systemic Idiopathic Juvenile Arthritis Treatment

1.2 Brief Introduction of Major Classifications

1.3 Brief Introduction of Major Applications

1.4 Brief Introduction of Major Regions

Chapter 2- Production Market Analysis:

2.1 Global Production Market Analysis

2.1.1 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

2.1.2 Major Manufacturers Performance and Market Share

2.2 Regional Production Market Analysis

Chapter 3- Sales Market Analysis:

3.1 Global Sales Market Analysis

3.2 Regional Sales Market Analysis

Chapter 4- Consumption Market Analysis:

4.1 Global Consumption Market Analysis

4.2 Regional Consumption Market Analysis

Chapter 5- Production, Sales and Consumption Market Comparison Analysis

Chapter 6- Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 7- Major Classification Analysis

Chapter 8- Major Application Analysis

Chapter 9- Industry Chain Analysis:

9.1 Up Stream Industries Analysis

9.2 Manufacturing Analysis

Continued here:
Systemic Idiopathic Juvenile Arthritis Treatment Market By Production, Manufacturer, Revenue Analysis And Forecast To 2029 - Bulletin Line

Read More...

This time last year I laughed and cried with my body – Thrive Global

Monday, December 30th, 2019

.

My grand daughter is 6 years old and my goal is to be physically and mentally fit to enjoy her. Well after five years it was not going so well. I had a very serious sit down conversation with self last year around this time. No more minute resolutions. No more unmet goals. No more start and stop diets. I need help; this has been a 65 + year journey and things were not going as well as I had hoped. I downloaded a habit tracker and put short doable daily and weekly goals. For movement, I have the following daily goals:

I also have a weekly hot yoga class at 7 AM on Sunday mornings that I look forward to. The class is 90 minutes of stretching and meditating in the heat which is awesome for arthritis which is in various places in my body.

Over the year, I lost weight, my flexibility increased and my diet shifted as I no longer craved foods that were not good for me. Honestly, I did other things such as increase my prayers, meditation, breathing and affirmation practices. But the key was the physical movement it always accelerated all the other practices. While I did not always do every practice every day, the habit tracker helped me stay on target by starting my count over when I missed a practice.

This year both my mind and body are in a better place than last year. The goal for 2020 is to add real cardio and reap more relief for sleep and stress. I joined my local gym last month; my plan is to enroll in a few classes and add it to my habit tracker. Slow progress is still progress.

Weekly Prompt

Follow this link:
This time last year I laughed and cried with my body - Thrive Global

Read More...

Find the right tools to garden with arthritis – austin360

Friday, December 27th, 2019

Helen Aristar-Dry likes to garden, but she doesnt want the aches and pains that could follow an enjoyable time spent out at her 1-acre property in Dripping Springs.

Ive always been interested in easier ways to garden, said Aristar-Dry, 73, who has had rheumatoid arthritis for about 50 years. For someone like herself, she said, Youre always looking for ways to lessen the strain on your joints.

Rheumatoid arthritis is an autoimmune and inflammatory disease that often affects hands, wrists, knees and ankles. Symptoms can include swelling, pain and stiffness in more than one joint, as well as fatigue and weakness.

Over the years having had several surgeries and used a wheelchair at times she has learned tactics to help her out. Sitting alongside her raised bed gardens used for growing Swiss chard and kale, along with other things she is glad she can still relish working with flowers, vegetables and dirt.

Its just really a good pastime, she said.

Aristar-Dry has a doctorate in linguistics, and after she retired in 2013, she had more time for a favorite hobby. She became a Hays County master gardener in 2015, and she has researched a variety of ways to make it easier for her in the garden.

Evaluating her resources and careful planning have helped, Aristar-Dry said. In addition to finding assistance for heavy jobs, she divides up large tasks into shorter chunks.

I rarely work more than 30 minutes at a time, she said. By then my hands will be hurting, so its time to quit.

If I overdo it, Im going to feel bad, she said. She also keeps a to-do list, so I can see whats a good job that fits the time I have. I dont do big projects.

In addition, she opts to use equipment that isnt weighty. I use a childrens rake with a long handle, because its much lighter, she said. Its less stress on the joints if you dont have to carry heavy stuff around. She uses a cart, rather than a wheelbarrow, to move large items such as bags of dirt.

She needs to be more vigilant about keeping her tools sharpened so they dont require as much strength to use, she said. Thats one I need to work on, but it makes a big difference.

Effective use of logistics has also aided her, and that can be as simple as storing her tools near the garden. Shes a big advocate of raised beds of all kinds where she can even sit down to work.

Theyre less demanding physically, she said. As well, she wishes she had more space between garden beds to allow more room for a bench or a cart to get through the path.

She carefully selects plants that are easier to care for, such as drought-tolerant natives, she said. As well, she likes to use plants that have been designated as Texas Superstars, which perform well under Texas tough growing conditions, according to texassuperstar.com.

Aristar-Dry prefers to use perennial plants rather than annuals, because with perennials, you put them in once and they come back, she said. Perennials are just much easier.

She keeps in mind some ergonomic principles, such as using her joints in a neutral position, which she described as about midpoint of their range, and other basics. In addition, she helps limit discomfort through the selection of ergonomically designed gardening tools. These tools help the user reduce stress and injuries from overuse of the body.

She has some long-handled tools that can help let her back remain straight. Some tools such as a waist-high weeder have an O-shaped handle that offers more grip surface, and its easy to use two hands with, she said.

Along with other selection criteria, she picks various tools that can let her keep her wrist straight, she said. (Often, she said, many tools require users to bend their wrists.)

Other implements can also help; she uses a special faucet turner to make it easier to turn on and off the water outside so she doesnt have to use as much strength. She uses a garden kneeler that can serve as a seat, she said. When I sit down and keep my back straight, I can work a whole lot longer.

Putting together information on the tactics she uses, as well as including more details about ergonomics and such, she has given a presentation on called Ergonomic Gardening: Gardening to Avoid Aches and Pains about a half-dozen times at the Hays County Master Gardeners Associations In the Garden series. Emphasizing that she doesnt have any medical training but that she has found these methods useful to her.

The talk is popular, said Phyllis Janowski, past president of the Hays County Master Gardeners Association.

People found it helpful to learn about some measures they could take, even for those who dont usually get aches and pains from gardening, she said.

Now that Aristar-Dry has found workarounds to help her, she still gets to take joy in the garden, she said. I think its really just rewarding to be out there with growing things.

Original post:
Find the right tools to garden with arthritis - austin360

Read More...

Food and ingredients to cure arthritis! – Elets

Friday, December 27th, 2019

Share

Share

Email

Listen to this Article

Arthritis is caused by inflammation of the joints. There are many foods and ingredients that can ease inflammation and may help relieve some of the joint pain associated with arthritis. Adding these foods to a healthy diet can help alleviate our arthritis symptoms. Lets have a look on list of food and ingredients that we can try using at our homes in order to get some relief from the arthritis-related pain.

Grains

While considering our options in the bread, cereal, and pasta, we should avoid refined grains. Not only are they highly processed grains but limited in nutrition, can lead to inflammation throughout the body. For Example, switching from refined flour to whole-wheat flour in our recipes can increase the intake of nutrients and potentially lower inflammation. Likewise, barley is filled with 6 grams of fiber per cup, a perfect addition to soups, stews and risotto dishes.

Nut and seeds

Nuts and seeds are a useful component in our diet. Most importantly it offers a variety of health benefits to people with arthritis. With their high ALA content, nuts like walnuts are omega-3-containing and researchers studying their effects have found that they lower C-reactive protein (CRP), an inflammation marker linked to an increased risk of cardiovascular disease and arthritis. Likewise, chia seeds are also an excellent source of anti-inflammatory ALA, but their greatest benefit is likely their high fiber content.

Fruit and vegetables

Fruits are naturally sweet and have a substantial amount of antioxidants, protein, vitamins, minerals, and other nutrients, just like red raspberries, tart cherries and strawberries are filled with antioxidants that help to get rid of radicals that encourage inflammation whereas Vegetables are rich in antioxidants and other nutrients that protect against cell damage and lower inflammation throughout the body, including in the joints. For example, fresh, leafy vegetables such as broccoli, spinach, brussels sprouts, kale, swiss chard, and bok choy are loaded with antioxidants such as vitamins A, C, and K which protect cells from free radical harm.

Spices

According to traditional Eastern medicine, ginger and turmeric are two spices that have anti-inflammatory properties. Along with its anti-inflammatory properties, some studies have shown ginger can also reduce osteoarthritis symptoms, if not in food one can also opt-in the form of a herbal supplement -like IMOVE containing popular, active and trusted pain management ingredients such as ginger and turmeric. It also includes Glucosamine & Chondroitin for joint repair and lubrication, thereby offering full joint treatment.

Fish

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are called marine fatty acids as they are derived from fish, adding omega-3 sources to our diets inflammation could be reduced. Fatty fish such as salmon, tuna, sardines, and mackerel are the best sources of marine omega-3s. Anti-inflammatory effects of omega-3s are helpful not only for the relief of arthritis but also for the prevention of other inflammatory diseases, such as heart disease. It is usually suggested to eat 3 to 6ounce serving of these fish two to four times a week to reduce inflammation and protect the heart Omega-3-rich fishes are also high in mercury, which causes brain and nervous system can harm if consumed in large quantities. Its important to choose smaller fish that have less mercury.

(Disclaimer: Writer is Sargam Dhawan, Director, Planet Herbs Lifesciences Pvt Ltd. Views expressed are a personal opinion.)

See the article here:
Food and ingredients to cure arthritis! - Elets

Read More...

Goldman’s 8 Highest-Conviction Health Care Stocks to Buy – Yahoo Finance

Friday, December 27th, 2019

Goldman Sachs is bullish on these health care stocks.

Last U.S. presidential election season, health care stocks didn't perform very well. Political headline risk related to drug pricing and "Medicare for All" could weigh on health care valuations again in 2020. Fortunately for investors, the Goldman Sachs analyst team says there are still plenty of opportunities for long-term investors to buy health care stocks heading into an election year. Goldman says valuations are reasonable, aggressive policy changes are unlikely, innovation and product development are booming and there is consolidation potential in the sector as well. Here are Goldman's eight high-conviction health care stock ideas for 2020.

Amgen (ticker: AMGN)

Amgen is a global biopharmaceutical company that markets drugs for oncology and inflammation. Analyst Terence Flynn says Amgen will likely outperform consensus revenue and earnings per share estimates in 2020 and 2021. After winning a patent battle against arthritis drug Enbrel in August and acquiring plaque psoriasis and psoriatic arthritis drug Otezla shortly thereafter, Flynn says Amgen is on track to grow revenue by between 4% and 8% annually over the next four years. Data on Tezepelumab and AMG 510 may also be near-term catalysts. Goldman has a "buy" rating and $279 price target for AMGN stock.

BioMarin Pharmaceutical (BMRN)

BioMarin is a biopharma company focused on the treatment of serious rare and ultra-rare diseases. Analyst Salveen Richter says BioMarin has a diversified portfolio of treatments that is positioned to deliver more than 20% revenue growth in 2020. Richter estimates BioMarin's seven core commercial products will generate a combined $1.7 billion in fiscal 2019 revenue and peak at more than $6 billion in combined revenue in 2030. Richter estimates peak sales for BioMarin's gene therapy treatment for hemophilia A at $1.3 billion. Goldman has a "buy" rating and $157 price target for BMRN stock.

Incyte Corp. (INCY)

Incyte is a biotech company focused on hematology, oncology and inflammation. Richter says Incyte's lead drug Jakafi is on track for $2.9 billion in peak 2028 sales. In addition, he says Incyte has a strong development pipeline of 21 drugs, with eight already in pivotal-stage clinical trials. Phase III Gravitas-301 data for itacitinib in steroid nave acute graft-versus-host disease should be a near-term catalyst. Richter is anticipating updates from the company's dermatology franchise in the first half of 2020. Goldman has a "buy" rating and $122 price target for INCY stock.

Iqvia Holdings (IQV)

Iqvia is a global advanced analytics, technology and life sciences research company. Analyst Robert Jones says Iqvia is a large-cap growth stock, and its research segment should be particularly strong in 2020. Jones says the market isn't fully appreciating Iqvia's technology segment, which is producing healthy organic revenue growth due to solid demand for real-world evidence. Jones says the election cycle could drive RWE demand in 2020, differentiating Iqvia from other health care stocks that have negative headline risk. Goldman has a "buy" rating and $191 price target for IQV stock.

UnitedHealth Group (UNH)

UnitedHealth is one of the largest global managed care organizations. Analyst Stephen Tanal says United's commercial, Medicare Advantage and Medicaid businesses are all attractive, and its Optum acquisition gives the company access to a unique collection of data and services. Goldman is projecting more than $19 billion in operating cash flow in 2020, with only about $2.3 billion needed for capital expenditures and share buybacks. Tanal says 2020 guidance is conservative, and UnitedHealth is well-positioned for at least 13% annual EPS growth. Goldman has a "buy" rating and $330 price target for UNH stock.

Vertex Pharmaceuticals (VRTX)

Vertex is a biopharma company focused on developing treatments for cystic fibrosis. Vertex is also developing a pipeline of therapies for pain, sickle cell disease, kidney disease and other conditions. Vertex shares gained 25% in the past three months, and Richter says Vertex is on track for impressive EPS growth in the coming years due to its multiple pipeline drivers. Goldman has a "buy" rating and $285 price target for VRTX stock.

Story continues

Dentsply Sirona (XRAY)

Dentsply Sirona is one of the largest manufacturers of dental office solutions, including consumables and high-end equipment. Analyst Nathan Rich says Dentsply Sirona's new Primescan intraoral scanner should benefit from long-term demand and be a major contributor to 2020 revenue growth. In the longer-term Primescan upgrade programs could drive additional revenue upside. In addition, new product launches and the company's One DS loyalty program could be bullish catalysts. Rich says the company's restructuring efforts appear to be ahead of schedule, suggesting potential margin growth opportunities ahead. Goldman has a "buy" rating and $66 price target for XRAY stock.

Zoetis (ZTS)

Zoetis is the global leader in animal health medicines and vaccines. Rich says Simparica Trio could be the world's first $1 billion animal health drug and has the potential to add as much as 30 percent to Zoetis EPS. Favorable pricing and product mix should contribute to cash flow growth and boost margins as well. Finally, Rich says the company's expansion to diagnostics and new pain drugs may be long-term growth opportunities as well. Pet care has also historically been relatively recession-proof, potentially limiting downside risk. Goldman has a "buy" rating and $148 price target for ZTS stock.

Goldman Sachs' top health care stocks for 2020:

-- Amgen (AMGN)

-- BioMarin Pharmaceutical (BMRN)

-- Incyte Corp. (INCY)

-- Iqvia Holdings (IQV)

-- UnitedHealth Group (UNH)

-- Vertex Pharmaceuticals (VRTX)

-- Dentsply Sirona (XRAY)

-- Zoetis (ZTS)

More From US News & World Report

See the article here:
Goldman's 8 Highest-Conviction Health Care Stocks to Buy - Yahoo Finance

Read More...

Rheumatoid Arthritis Treatment Market Industry Analysis, Trend and Growth, 2017-2027 – Info Street Wire

Friday, December 27th, 2019

Study on the Rheumatoid Arthritis Treatment Market

The comprehensive report published by Future Market Insights (FMI) offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Rheumatoid Arthritis Treatment Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Rheumatoid Arthritis Treatment Market during the forecast period 2017-2027.

As per the findings of the presented study, the Rheumatoid Arthritis Treatment Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period 2017-2027. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Rheumatoid Arthritis Treatment in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.futuremarketinsights.co/reports/sample/REP-GB-3119

The presented study addresses the following queries related to the Rheumatoid Arthritis Treatment Market:

The presented market report dives deep into understanding the business strategies adopted by leading market players in the global Rheumatoid Arthritis Treatment Market. Further, the SWOT analysis for leading market players is enclosed in the report along with the revenue share, pricing analysis, and product overview of each company.

The extensive study on the Rheumatoid Arthritis Treatment Market pinpoints the different factors that are likely to influence the prospects of the Rheumatoid Arthritis Treatment Market in each region.

Decisive Information Enclosed in the report:

Get Access To TOC Covering 200+ Topics athttps://www.futuremarketinsights.co/toc/REP-GB-3119

key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customized Report As Per Your Requirements athttps://www.futuremarketinsights.co/customization-available/REP-GB-3119

Why Buy from FMI?

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

T (UK): + 44 (0) 20 7692 8790

This post was originally published on Info Street Wire

Read the rest here:
Rheumatoid Arthritis Treatment Market Industry Analysis, Trend and Growth, 2017-2027 - Info Street Wire

Read More...

Drugs for Rheumatoid Arthritis Market 2019 Global Share, Trend, Segmentation and Forecast to 2025 – Market Research Sheets

Friday, December 27th, 2019

Global Drugs for Rheumatoid Arthritis Market research report gives a comprehensive outlook of the markets 2019-2025 and offers an in-depth summary of the current market status, historic, and expected way forward for the Drugs for Rheumatoid Arthritis Market. Additionally, to this, the report provides data on the restraints negatively impacting the markets growth. The report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the Market.

Download Free Sample Copy of Drugs for Rheumatoid Arthritis Market Report: https://dataintelo.com/request-sample/?reportId=73051

Key Objectives of Drugs for Rheumatoid Arthritis Market Report: Study of the annual revenues and market developments of the major players that supply Drugs for Rheumatoid Arthritis Analysis of the demand for Drugs for Rheumatoid Arthritis by component Assessment of future trends and growth of architecture in the Drugs for Rheumatoid Arthritis Market Assessment of the Drugs for Rheumatoid Arthritis Market with respect to the type of application Study of the market trends in various regions and countries, by component, of the Drugs for Rheumatoid Arthritis Market Study of contracts and developments related to the Drugs for Rheumatoid Arthritis Market by key players across different regions Finalization of overall market sizes by triangulating the supply-side data, which includes product developments, supply chain, and annual revenues of companies supplying Drugs for Rheumatoid Arthritis across the globe

Major Players included in this report are as follows AbbVie IncHoffman-La Roche AGAmgen IncPfizer IncBristol-Myers Squibb CoJohnson & JohnsonUCB Biosciences IncMitsubishi Tanabe Pharma CorpBiogen IncMerck & CoMarket Segment by Product TypePharmaceuticalsBiopharmaceuticals

Drugs for Rheumatoid Arthritis Market can be segmented into Product Types as PrescriptionOTC

Drugs for Rheumatoid Arthritis Market can be segmented into Applications as HospitalClinicsOther

To Buy this report, Visit https://dataintelo.com/checkout/?reportId=73051

Drugs for Rheumatoid Arthritis Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

Target Audience: Drugs for Rheumatoid Arthritis Equipment Manufacturers Traders, Importers, and Exporters Raw Material Suppliers and Distributors Research and Consulting Firms Government and Research Organizations Associations and Industry Bodies

Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels. When tracking the trends researchers have made a conscious effort to analyse and interpret the consumer behaviour. Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.

Customize Report and Inquiry for The Drugs for Rheumatoid Arthritis Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=73051

Report structure:In the recently published report, DataIntelo.com has provided a unique insight into the Drugs for Rheumatoid Arthritis Industry over the forecasted period. The report has covered the significant aspects which are contributing to the growth of the global Drugs for Rheumatoid Arthritis Market. The primary objective of this report is to highlight the various key market dynamics listed as drivers, trends, and restraints.

These market dynamics have the potential to impact the global Drugs for Rheumatoid Arthritis Market. This report has provided the detailed information to the audience about the way Drugs for Rheumatoid Arthritis industry has been heading since past few months and how it is going to take a shape in the years to come.

DataIntelo has offered a comprehensive analysis of the Drugs for Rheumatoid Arthritis industry. The report has provided crucial information about the elements that are impacting and driving the sales of the Drugs for Rheumatoid Arthritis Market. The section of competitive landscape keeps utmost importance in the reports published by DataIntelo. Competitive landscape section consists of key market players functioning in the worldwide industry of Drugs for Rheumatoid Arthritis.

The report has also analysed the changing trends in the industry. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the Drugs for Rheumatoid Arthritis Market.

Table of Contents1 Industry Overview of Drugs for Rheumatoid Arthritis2 Manufacturing Cost Structure Analysis3 Development and Manufacturing Plants Analysis of Drugs for Rheumatoid Arthritis4 Key Figures of Major Manufacturers5 Drugs for Rheumatoid Arthritis Regional Market Analysis6 Drugs for Rheumatoid Arthritis Segment Market Analysis (by Type)7 Drugs for Rheumatoid Arthritis Segment Market Analysis (by Application)8 Drugs for Rheumatoid Arthritis Major Manufacturers Analysis9 Development Trend of Analysis of Drugs for Rheumatoid Arthritis Market10 Marketing Channel11 Market Dynamics12 Conclusion13 Appendix

Ask for Discount on Drugs for Rheumatoid Arthritis Market Report at: https://dataintelo.com/ask-for-discount/?reportId=73051

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataInteloName Alex MathewsEmail [emailprotected]Website https://dataintelo.comAddress 500 East E Street, Ontario, CA 91764, United States.

This post was originally published on Market Research Sheets

See original here:
Drugs for Rheumatoid Arthritis Market 2019 Global Share, Trend, Segmentation and Forecast to 2025 - Market Research Sheets

Read More...

Global Septic Arthritis Treatment Market Growth (Status and Outlook) 2019-2024 | Exclusive Report by Magnifier Research – Market Research Sheets

Friday, December 27th, 2019

Global Septic Arthritis Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024offers an orderly representation of the market that proposes a positive growth rate in the upcoming years. The report contains the combinations, methods, summarized study, and data gathered from various sources. The research experts have studied the historical data and provided an idea of the direction this market will take in the forthcoming years. The report involves key insights pertaining to industry deliverables, particularly market trends, market share, market competitors and recognized players, market size, current valuation, and revenue estimations for the forecast period from 2019 to 2024. The research study is reliable, wide-ranging, and the result of strong analytical research on theSeptic Arthritis Treatmentmarket.

Get Free Sample Copy of Report/Sample Request @https://www.magnifierresearch.com/report-detail/5571/request-sample

The report investigates evaluates theSeptic Arthritis Treatmentmarket on the basis of market segments and geographical areas and current market trends. Various factors such as development, rapidly increasing demand, economic stability are directly and indirectly fuelling growth in the market are also covered in the report. An assessment of the technical barriers, other issues, as well as market restraints is determined. Key market competitors who majorly hold the market shares in terms of demand, supply, and income through their products, services, and after deal processes are studied and their comprehensive abstract has been provided in the report.

The report encloses a precise evaluation of theSeptic Arthritis Treatmentmarket, including growth rate, current scenario, and volume inflation prospects, on the basis of Porters Five Forces analysis. It provides reliable and authentic projections regarding the market. The report has thoroughly studied the market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue.

Lupin Pharmaceuticals (US), F. Hoffmann-La Roche Ltd (Swtizerland), AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Pfizer (US),

The global version of this report with a geographical classification such as:

North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Get Full Report With TOC @https://www.magnifierresearch.com/report/global-septic-arthritis-treatment-market-2019-by-company-5571.html

This comprehensive report will

Moreover, manufacturing base distribution, production area, and product type, concentration rate mergers & acquisitions, expansion are provided in the report. The report further has included a new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis. It also delivers vital information referring to the industrys concentration ratio.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

This post was originally published on Market Research Sheets

Link:
Global Septic Arthritis Treatment Market Growth (Status and Outlook) 2019-2024 | Exclusive Report by Magnifier Research - Market Research Sheets

Read More...

Auranofin Market Status And Forecast 2027, By Players, Types And Applications – Market Research Sheets

Friday, December 27th, 2019

Auranofin is a gold-containing salt with chemical formula and name C20H34AuO9PS and Gold, 2,3,4,6 tetraacetate respectively. It is used for treatingarthritis and is classified as an antirheumatic agent by World Health Organization and is also called disease-modifying antirheumatic drug (DMARD). Antirheumatic drugs are the ones that are used in the treatment of rheumatism. Auranofin is known by different names in different countries. Auranofin improves arthritis symptoms like painful, tender and swollen joints and morning stiffness. Also, it is said to decrease the pain by reducing inflammation and it slows down or stops the immune system from attacking the joints and Auranofin acts by inhibiting DNA synthesis. Auranofin should be considered only when other non-steroidal anti-inflammatory drugs and appropriate steroids are ineffective in controlling the symptoms of rheumatoid arthritis.

The use of Auranofin is increasing as the number of people having arthritis is increasing. This can driveauranofin marketas it is effective and is reported to exhibit less serious side effects as compared to other drugs that are used for treating arthritis.

Planning to lay down future strategy? Perfect your plan with ourreport brochurehere

Increasing Demand for Auranofin Owing to Rising Arthritis Demographics

According to CDC reports, arthritis is still a serious health crisis in the U.S. and it is a global epidemic as well. Recent estimates showed that nearly 91 million Americans might have arthritis (37%), including one- third of those aged bwtween18 to 64 plus 300,000 children approximately. The underlying reasons for the increasing population with arthritis are obesity, lack of physical activity, Vitamin D deficiency and others. Also, Arthritis is rising in Europe, Latin America and in Middle East Africa and reasons being sedentary lifestyle and in some cases, heredity. The growing population with arthritis is anticipated to fuel the Auranofin market as it is less severe than the other drugs that serve the same purpose.

Want to know the obstructions to your companys growth in future?Request a Custom reporthere

The Auranofin market is rising because of the growing arthritis population and it is expected to grow in the coming years. The key players of Auranofin include Ferro Pfanstiehl Laboratories, Inc.,Prometheus laboratories inc, JOHNSON MATTHEY INC, Lek Pharmaceuticals d.d, Medichem SA and Company Overview ofLonza Group Ltd and others. Apart from them, more industrialists and manufacturers are showing a keen interest in the Auranofin as the demand for the auranofin, due to the rising population with arthritis is growing and is expected to escalate until and unless people dont practice healthy lifestyle and engage themselves in physical activities.

This post was originally published on Market Research Sheets

View original post here:
Auranofin Market Status And Forecast 2027, By Players, Types And Applications - Market Research Sheets

Read More...

‘Your Songs Will Live On. You Will Be Missed.’ Rick Charette Leaves The Stage – Maine Public

Friday, December 27th, 2019

Beloved Maine childrens singer Rick Charette and his Bubblegum Band played their 29th annual holiday concert at St. Josephs College earlier this month. It was a sold-out show, standing room only. As always, the price of admission was a new, unwrapped toy for a child in need.

Its likely to be Charettes final public performance ever.

Health challenges are forcing the 72-year-old author of Alligator in the Elevator and I Love Mud off the stage. But he doesnt want to make a big deal of it.

Id like to have people thinking of the music when they think of me, rather than my physical condition, Charette said. Thats why Im downplaying it.

He hinted at his retirement back in 2018, and while Charette is reluctant to talk about specifics, he said a combination of arthritis, a nagging shoulder injury and a touch of Parkinsons disease are making it difficult to perform his energetic shows. Charette would rather stop while hes still at the top of his game, rather than fizzle out and fade away.

I knew I should have said something about it being the last one, but I just couldnt bring myself to do it, Charette said. It would have been just too sad.

For now, hes telling people who want to book him to call back in the spring, when he might feel better. Charettte knows thats not likely, though.

Im ever hopeful but still accepting that, at some point, some things are the way they are, he said.

In the meantime, Charette can look back on an exceptional 35-year career of writing, singing and making children happy.

Charette grew up in Westbrook. When he graduated from Cheverus High School in 1965, music was already a big part of his life.

Pete Seeger was my hero in terms of what he could do to have the whole audience in the palm of his hand, singing along, Charette said over a cup of coffee at his kitchen table in Windham.

He also admired Bob Dylans songwriting.

While earning a degree in English at the University of Southern Maine, Charette found moderate local success as a folksinger, wielding an acoustic guitar, dulcimers and the occasional banjo. He played the bar and coffeehouse circuit and opened for better-known acts such as Tom Rush.

He wasnt always happy, though.

Playing for adults, I was a nervous wreck, Charette said. It was painful. Then, I played a little bit for kids, and it was a whole different vibe. I seemed to relax and be comfortable.

He knew hed found his niche.

Singing with kids meant he did not have to play in smoky bars anymore where the music was secondary to drinking and gabbing. Kids didnt yell requests for Neil Young all night, either.

I liked the hours a lot better, Charette said.

Bubble Gum was the first childrens song he wrote. Kids immediately latched on to its gentle, bouncing cadence and quirky lyrics: I dont like frog legs cause they smell like feet. You can take away the liver. Give me something sweet Bubble gum, bubble gum. Lots of fun with my bubble gum.

By 1983, Charette had recorded an albums worth of original material. He also scored a distribution deal with Activity Records.

When the record came out, it gave me credibility as a performer for kids, he said.

The company passed on his second batch of songs in 1985. They thought Charettes tunes werent educational enough. They wanted more colors and numbers.

At that juncture, Charette and Roy Clark, his piano player and arranger, hatched a plan. They both mortgaged their homes and started their own company, Pine Point Records. Their first release was the album Alligator in the Elevator.

That went on to sell several hundred thousand copies, Clark said.

Charettes best-known song, I Love Mud, appeared on that record.

All I have to do is sing, Mud, mud, I love mud, and everyone finishes the rest of the chorus, Charette said. And its usually the grown-ups singing loudest.

Clark said its Charettes ability to listen to kids, to take their interests seriously, that makes him a good songwriter. Instead of deciding what a child should be singing, he finds out what kids want to sing about.

Thats special. Thats unique, Clark said.

All told, Pine Point Records released 11 albums by Charette. The latest came in 2016.

With a hit childrens record, Charette was soon playing concerts and teaching school songwriting workshops across the country. Many of Charettes his best-loved songs include hand motions or sign language to help keep wee ones engaged. Skunk, bear and alligator puppets also played prominent roles in his performances.

Its beautiful pandemonium, said bassist Mike Burd of Industry. Burds played in the Bubblegum Band for about three years. Rick is a totally humble, gentle, self-effacing, completely transparent, honest guy. The kids fall all over him and follow him all around. The parents do the same thing and, in many cases, the parents parents did the same thing. He has this multigenerational audience. Everybody knows all the words to every song.

Charette has always shied away from politics or broad moralizing in his songs, focusing instead on warmth, fun and singability.

I just want it to be a happy time for them, he said. I think it makes a difference for kids, later in life just knowing someone cares for them giving them that time to play.

Its been a good life for Charette. Hes a happily married father of three and grandfather of two. Hes a longtime resident of Windham, living in an immaculate condo with access to Sebago Lake. Recently, however, hes started to feel his age.

My 60s were good, Charette said. But it seems like when I hit 70, I hit a wall.

Thats when he had a bicycle accident. Charette broke his collarbone and a few ribs, going down hard on a hidden curb.

The bones healed, but his shoulder has never been the same, making it hard to play the guitar. Charette also has arthritis and Parkinsons disease which hes opening up about for the first time.

Ive been reluctant to put that out there in public, he said. Its just the beginning stages and sometimes, when people know something like that about you, they start treating you differently.

He doesnt want that. Charettes early symptoms are manifesting mostly in tight muscles. They make it hard to move around. His feet often feel leaden, immobile.

I wouldnt want to present that onstage. You want kids dancing around, he said. In my mind, in my head, Im still right there. But physically, its just too difficult.

Looking ahead, Charette dreams of hiking when the weather gets nice again. He also imagines days when he might feel well enough to volunteer singing with children, stuck in the hospital. Hes still thinking up songs, too. Charette recently wrote one about Windham and gave it to a local schoolteacher.

Some days are better than others, and when they are, I try to make the most of them, Charette said.

He thinks about his musical legacy, pondering what its meant to himself and the thousands of children hes sung songs with.

Thats something Ive wondered, Charette said. Will this just be time that was taken up? Will they really remember any of it?

As news of his retirement spreads, hes getting his answer.

Cards, letters and Facebook messages are starting to pour in. People tell him about the impact his music had on their lives and now on their childrens lives.

He performed at my school all the time. I had Ricks records on my Christmas list in the 80s when I was a kid, said Heather Hilton, who grew up in Limington. Last year his downloads were on my sons wish list.

Hilton said her 5-year-old son especially likes Charettes epic song Where Do My Sneakers Go at Night? Hiltons mother, an elementary school teacher, still plays Charettes songs in her classroom and said her pre-K students still love them.

One card Charette received this month reads: From my birthday party in kindergarten, to Baxters first concert, youve made us smile throughout the years. Thank you for your wonderful gift of music. Your songs will live on. You will be missed.

It came with a smiling family portrait and was signed, Allyson, Baxter and Tristan.

After his final concert, one little girl waited in line to meet Charette. When it was her turn, she handed him a crinkled drawing of a snowman. It was signed, in pencil, From Athena.

I dont think its sunk in, yet, Charette said, looking at the drawing and the card. Sometimes, I beat myself up. I wish I could do more. Then, I have to remind myself to feel good about the things Ive already done.

Clark thinks Charettes music will be around long after both of them are gone. He points out that I Love Mud and Alligator in the Elevator are so familiar in the kid world, that many people mistake them for traditional folk songs in the public domain.

That seems to suit Charette just fine.

If I had to sum up the whole thing, Im just so gratified that Ive had this run, this experience, Charette said. Its always been the words and the music and the kids.

This story appears through a media sharing agreement with Bangor Daily News.

Go here to see the original:
'Your Songs Will Live On. You Will Be Missed.' Rick Charette Leaves The Stage - Maine Public

Read More...

Insulin Resistance Linked to Rheumatoid Arthritis Flares – Rheumatology Network

Wednesday, December 25th, 2019

Insulin resistance is independently associated with body mass index (BMI) and synovitis in rheumatoid arthritis patients, shows new research published in Arthritis and Rheumatology.

Led by Ronan H. Mullan of the Trinity Centre for Health Science in Dublin, Ireland, researchers wrote that the findings, which were published December 16, suggest a link between glucose levels and rheumatoid arthritis (RA) inflammation.

RA and type 2 diabetes mellitus (T2MD) share many of the same characteristics. Both are powered by abnormal glucose metabolism and both are associated with insulin resistance and adverse cardiovascular disease outcomes.

In this study, researchers recruited 92 rheumatoid arthritis patients (mean age 59, 66% female) who were assessed for insulin resistance, BMI and rheumatoid arthritis disease activity. Researchers found thatglucose transporters GLUT1 and GLUT4 were heightened in the synovial tissues of rheumatoid arthritis patients, but not in those of osteoarthritis patients. And, GLUT1 was present in increased levels within all layers of the RA synovium. This suggests an independent association between insulin resistance (particularly with obesity) and the degree of RA disease activity and synovitis.

RELATED:Diabetes and RA: Explaining the Similarities

This data provides direct evidence that insulin resistant pathways are preferentially expressed within inflamed tissues in RA. And, they suggest a potential mechanism by which the reprogramming of glucose handling through differential GLUT expression favors the perpetuation of inflammation, researchers wrote.

METFORMIN

Taking metformin, a first-line treatment for type 2 diabetes mellitus, was shown to reduce inflammation in synovial tissue of at least five patients by decreasing the spontaneous production of IL-6, IL-8 and MCP-1 in synovial cells and fibroblasts.

We confirmed that metformin treatment increased the phosphorylation of AMPK and reduced the expression of GLUT1 from synovial fibroblasts. Furthermore, we demonstrated that metformin is capable of altering the cellular metabolic activity. This is consistent with recent studies suggesting metformin promotes resolution of inflammation through altered cellular metabolic activity, researchers wrote.

THE FINDINGS

REFERENCE: Lorna Gallagher Sian Cregan Monika Biniecka, et al. "Insulin Resistant Pathways are associated with Disease Activity in Rheumatoid Arthritis and are Subject to Disease Modification through Metabolic Reprogramming; A Potential Novel Therapeutic Approach," Arthritis and Rheumatolology. Dec. 16, 2019. https://doi.org/10.1002/art.41190

See more here:
Insulin Resistance Linked to Rheumatoid Arthritis Flares - Rheumatology Network

Read More...

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory…

Wednesday, December 25th, 2019

DetailsCategory: More NewsPublished on Tuesday, 24 December 2019 15:04Hits: 334

-- Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohns Disease and Psoriatic Arthritis --

FOSTER CITY, CA, USA & TOKYO, Japan I December 24, 2019 I Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo, Japan) and Eisai have entered into an agreement for the distribution and co-promotion of filgotinib, an investigational, oral, selective JAK1 inhibitor, in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA). Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications. The companies will jointly commercialize the medicine if approved.

Approximately 600,000 to 1 million people are living with RA across Japan, and despite available options, many still do not experience disease remission. In the global Phase 3 FINCH studies, filgotinib demonstrated durable efficacy and safety results across multiple RA patient populations, including in people with prior inadequate response to methotrexate treatment (MTX), those who were intolerant to one or more biologic treatments and those who were MTX treatment-nave.

We are very pleased to announce this important new partnership with Eisai, which brings together our complementary expertise and commitment in inflammation, to deliver this important new option to patients living with inflammatory diseases in Japan, said Luc Hermans, M.D., President and Representative Director, Gilead Japan.

We have extensive clinical development and commercialization experience spanning more than 20 years in RA and have established a solid RA franchise in Japan, said Hidenori Yabune, President of Eisai Japan, Senior Vice President of Eisai. With this agreement, we look forward to contributing more to patients living with RA by adding filgotinib to our product line-up.

Global studies investigating filgotinib in additional diseases are also underway, including the Phase 3 SELECTION trial in ulcerative colitis, the DIVERSITY Phase 3 trial in Crohns disease, the Phase 3 PENGUIN trials in psoriatic arthritis, as well as Phase 2 studies in uveitis and in small bowel and fistulizing Crohns disease.

Gilead and Galapagos NV (Mechelen, Belgium) have entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. Filgotinib is an investigational drug whose efficacy and safety have not been established. Filgotinib is pending regulatory approval in Japan, Europe and the United States, based on global Phase 3 trials evaluating its efficacy and tolerability.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the companys website at http://www.gilead.com.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit http://www.eisai.com/.

SOURCE: Eisai

See the original post:
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory...

Read More...

Adults with JIA Satisfied with Biologics But Often Fail to Adhere to Therapy, Study Finds – Juvenile Arthritis News

Wednesday, December 25th, 2019

Adults with juvenile idiopathic arthritis (JIA) treated with disease-modifying antirheumatic drugs (DMARDs) are more satisfied with biological medicines than with synthetic therapies such as methotrexate, a study based on patient questionnaires suggests.

Nonetheless, less than half of these patients took these medications as recommended.

The study, Treatment Satisfaction with and Adherence to DiseaseModifying Antirheumatic Drugs in Adult Patients with Juvenile Idiopathic Arthritis, was published in Arthritis Care & Research.

DMARDs are one class ofmedications currently used to treat JIA, and include both synthetic (chemical compound) medicines, such as methotrexate, and biological therapies.

Following prescribed treatment regimens as recommended (adherence) is a key requirement for clinical benefit. However, studies have found that just over half of rheumatoid arthritis patients comply with treatment regimens.

Such research in JIA has focused on children, but as40-60% of patients continue to experience symptoms into adulthood, a better understanding of the adherence to DMARDs in adults with this disorder is needed.

A team in Norway contacted adults with JIA, who as children had participated in a three-year study. From a total of 196 eligible patients, 96 (mean age of 25.1) agreed to participate.

The researchers collected information about medication use, and patients were given a series of questionnaires, which included a patient reports of active joint swelling.

Satisfaction with treatment was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM), which evaluates effectiveness, side effects, convenience, and overall satisfaction. In turn, medication adherence was assessed using the Morisky Medication Adherence Scale (MMAS-8), where 8 is high adherence and below 6 is low adherence.

Physical and mental health-related quality of life (HRQOL) was determined with the Short-Form Health Survey version 2, physical disability with the Health Assessment Questionnaire Disability Index, pain with the Brief Pain Inventory Short Form, and symptoms of psychological distress with the Hopkins Symptom Checklist.

Nineteen years after their diagnoses, 52 patients (54%) used synthetic DMARDs and/or biological DMARDs. Biological DMARDs were used by 37 patients (39%), either alone or in combination with methotrexate or sulfasalazine. Twenty-eight patients used methotrexate exclusively or in combination with biological DMARDs and sulfasalazine, while two patients used sulfasalazine alone.

Those using biological DMARDs alone reported significantly higher satisfaction with the medication related to effectiveness and overall satisfaction compared to those taking methotrexate. Participants using combination therapy also reported significantly higher satisfaction using biological DMARDs over methotrexate, based on side effects and overall satisfaction.

Lower satisfaction with medications was linked to pain intensity, physical disability, psychological distress, and active joints. Higher satisfaction related to effectiveness was strongly associated with a higher physical HRQOL, while overall satisfaction was linked with better physical and mental HRQOL.

The study also found that 46% of the patients reported low adherence to DMARDs, while 29% reported medium adherence, and 25% had high adherence.

Adherence to treatment was independent of age, gender, disease duration and course, active joints, effectiveness, side effects, and overall satisfaction. Treatment convenience was the only factor significantly linked to medication adherence.

In conclusion, JIA patients medication satisfaction was higher with bDMARDs [biological DMARDs] than MTX [methotrexate] 19 years after disease onset, the researchers wrote.

Knowledge and incorporation of patients experience with medication is important in order to promote patient centered care and achieve the best possible HRQOL, they added.

Total Posts: 11

Jos is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.

See the original post here:
Adults with JIA Satisfied with Biologics But Often Fail to Adhere to Therapy, Study Finds - Juvenile Arthritis News

Read More...

Think Twice When Choosing Skin Care Products as Gifts for Kids with JA – Juvenile Arthritis News

Wednesday, December 25th, 2019

As I searched online for Christmas presents for my loved ones recently, I browsed selections of pre-made gift kits. Many of them were bath or skin care based. I saw adorable bubble bath sets for children, makeup and nail kits, and baskets of soaps and creams marketed to young men and women.

Skin care products can make lovely gifts. I bought a unicorn tumbler full of bath bombs for my young cousin. But as I shopped, I thought about how I wouldnt buy gifts like these for myself. As someone withjuvenile-onset psoriatic arthritis, I would worry that they might flare my skin. I realized many of these gifts wouldnt be suitable for kids or young adults with juvenile rheumatic conditions.

Additionally, conditions such as systemic arthritis, dermatomyositis, scleroderma, psoriatic arthritis, and lupus can cause rashes, lesions, and other skin issues, which can be further irritated by skin care products.

Those with skin conditions cant usually tolerate the ingredients used in pre-made bath sets and makeup kits. Items such as bath bombs are not recommended for those with particular skin conditions. Other products may be drying and irritating to those with sensitive or inflamed skin.

But that doesnt mean you have to avoid giving pampering gifts altogether. Many kids with juvenile arthritis benefit from the soothing effects of a warm bathand the confidence boost of wearing makeup. Instead, when choosing a gift, consider the products quality.

If youre thinking of giving soaps, makeup, and lotions as gifts dont be afraid to ask the childs parents which products they use. And stick to those brands. Dont be misled by product labels containing words like natural, healing, or even psoriasis-friendly. While the claims might be valid, its best to stick to products that the family already trusts the brands they use are likely either doctor recommended or theyve discovered them after much trial and error.

Quality is essential for those living with chronic skin conditions. Dont be surprised if the products and brands that the person uses are a little expensive. You dont need to break your budget, but remember that its better to choose quality over quantity. A trusted eye shadow palette with one or two colors is worth much more than another with multiple shades that may irritate the skin.

You might also consider gifting skin care accessories such as makeup brushes or sponges, or a cosmetic bag to keep products in.

You could put together a custom-made bath kit. For younger kids, a bath caddy filled with bath toys and crayons, a hooded towel, a brush and comb, and fun, colored puffs. Older kids and teens might prefer bathrobes, slippers, eye pillows, spa socks, and candles or essential oils. I like this idea because you can pick and choose each item and customize it to the recipient.

Ive received lots of bath and beauty products in the past. Many of them came from my parents, who knew how careful I needed to be with skin products. Im always extremely appreciative of the lotions, makeup, and perfumes they gift, particularly as they can be pricey.

Sometimes Ive received products that I didnt feel comfortable using. But I accepted them with a smile and a genuine thank you. Im grateful for the gift of someone thinking of me, taking the time to buy me a gift, and wrap it up.

***

Note: Juvenile Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Juvenile Arthritis News, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to juvenile arthritis.

Elizabeth Medeiros is a young adult who has dealt with juvenile arthritis since she was a small child. However, her pain hasnt stopped her from working on a product design degree in Boston. Her passion is to create products that make life easier for the chronically ill, such as shoes and walking canes. When shes not in class, Elizabeth enjoys writing about how shes coped with arthritis at such a young age. You can find more of her writings at ArthritisGirl.Blogspot.com and on Instagram @GirlWithArthritis.

See the original post:
Think Twice When Choosing Skin Care Products as Gifts for Kids with JA - Juvenile Arthritis News

Read More...

Global Glucosamine Market 2020-2024 | Evolving Opportunities with Blackmores Ltd. and Cargill Inc. | Technavio – Business Wire

Wednesday, December 25th, 2019

LONDON--(BUSINESS WIRE)--The global glucosamine market is expected to grow by USD 229.19 million during 2020-2024, according to the latest market research report by Technavio, progressing at a CAGR of more than 6% during the forecast period. The market is driven by factors such as increasing use of combination therapy, popularity of e-commerce in the healthcare industry, and rising geriatric population. Request a free sample report

The market research report segments the glucosamine market by application (arthritis and other applications) and geography (Asia, Europe, North America, and ROW).

https://www.technavio.com/report/glucosamine-market-industry-analysis

Glucosamine Application Outlook (Revenue, USD Million, 2020-2024)

Glucosamine finds a large number of applications in the arthritis segment. The market is witnessing a shift toward the use of nutrachemicals and dietary supplements such as glucosamine to treat arthritis without side effects. Globally, the geriatric population is increasing significantly, leading to a prevalence of arthritis as the cartilage is more susceptible to wear with age. These factors are boosting the growth opportunities for market participants in the arthritis segment.

Glucosamine Regional Outlook (Revenue, USD Million, 2020-2024)

North American region led the market in 2019, followed by Europe, Asia, and ROW, respectively. During the forecast period, the North American region will continue to dominate as the largest market for glucosamine. This is due to the increasing sales of OTC glucosamine products and the rising prevalence of joint-related indications such as osteoarthritis. The expansion of the geriatric population in the region is also contributing to the growth of the glucosamine market.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Major Five Genetic Testing Companies:

Blackmores Ltd., Cargill Inc., Ethical Naturals Inc., GNC Holdings Inc., and Herbs Nutriproducts Pvt. Ltd. are among the vendors who have a strong position in the global market.

Blackmores Ltd.

Blackmores Ltd. operates the business across segments such as Australia and New Zealand, China, Other Asia, and BioCeuticals Group. Glucosamine + Fish Oil, Glucosamine Sulfate 1500 One-A-Day, Glucosamine Sulfate Complex 1000, Joint Formula Advanced, Joint Formula with Glucosamine & Chondroitin, and Vegetarian Glucosamine Sulfate Complete 1000 are some of the key offerings of the company.

Cargill Inc.

Cargill Inc. operates the business across segments such as Animal nutrition and protein, Animal nutrition and protein, Food ingredients and applications, Origination and processing, and Industrial and financial services. Regenasure is one of the key offerings of the company. It is glucosamine hydrochloride synthesized from corn. It is available in the form of a granular powder and is certified for Kosher Pareve, Kosher for Passover, and Halal use.

Ethical Naturals Inc.

Ethical Naturals Inc. operates the business through its Unified business segment. GreenGrown, which is glucosamine hydrochloride synthesized from vegetarian sources, is one of the key offerings of the company. It is available in the form of granular powder and can be used for improving joint health.

GNC Holdings Inc.

GNC Holdings Inc. operates the business across segments such as the US and Canada, International, and Manufacturing / Wholesale. GNC GLUCOSAMINE 1000 MG, GNC MSM-GLUCOSAMINE, GNC GLUCOSAMINE SULFATE 500 MG, DOCTOR'S BEST, and GNC TRIPLE STRENGTH GLUCOSAMINE CHONDROITIN are some of the key offerings of the company.

Herbs Nutriproducts Pvt. Ltd.

Herbs Nutriproducts Pvt. Ltd. operates the business across segments such as Natural infusion tea, Cold pressed oils, Functional foods, Vitamins and supplements, and Beauty. Glucosamine Chondroitin Complex with Herbal Extracts is one of the key offerings of the company. It is a combination of glucosamine sulfate and chondroitin available in the form of tablets.

Technavio provides a free sample report which contains multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

See more here:
Global Glucosamine Market 2020-2024 | Evolving Opportunities with Blackmores Ltd. and Cargill Inc. | Technavio - Business Wire

Read More...

Cultural Adaptation and Validation of the Methotrexate Intolerance Severity Score in Brazilian Portuguese for Adults With Rheumatoid Arthritis -…

Wednesday, December 25th, 2019

INTRODUCTION:

The Methotrexate Intolerance Severity Score (MISS) questionnaire is used to identify intolerance to methotrexate (MTX), but it is not available in the Brazilian Portuguese language.

The aim of this study was to adapt and validate the MISS in Brazilian Portuguese.

The Brazilian Portuguese version of the MISS was developed following the Guidelines for the Process of Cross-cultural Adaptation of Self-report Measures. The new version was tested in 120 patients with rheumatoid arthritis. For the reliability assessment, the Cronbach coefficient was used. The receiver operating characteristic curve was constructed with the objective of finding the best cutoff point for MTX intolerance and weighing the sensitivity and specificity. The concordance among the results was analyzed using the coefficient and factorial analysis with varimax rotation.

This methodological study developed and applied a culturally acceptable Brazilian Portuguese version of the MISS. The MISS questionnaire presented internal consistency classified as very good because Cronbach is equal to 0.83 (95% confidence interval, 0.79-0.87). The suitability of the data for factorial analysis was demonstrated using the Kaiser-Meyer-Olkin sample adequacy test (KMO = 0.723) and Bartlett sphericity test ( = 499.98, p < 0.001). It was observed that a factorial analysis with 3 factors is preferred; the receiver operating characteristic curve of the MISS score was considered the cutoff point at 6 points (sensitivity 100% and specificity 89.4%).

The Brazilian Portuguese version of the MISS is valid and reliable for the detection of MTX intolerance in clinical practice.

Visit link:
Cultural Adaptation and Validation of the Methotrexate Intolerance Severity Score in Brazilian Portuguese for Adults With Rheumatoid Arthritis -...

Read More...

Knee injuries in early adulthood may hasten arthritis – Reuters

Monday, December 23rd, 2019

(Reuters Health) - Young adults who have had knee injuries are much more likely than uninjured peers to develop arthritis in the knee by middle age, especially if they have broken bones or torn connective tissue, a recent study suggests.

Researchers followed almost 150,000 adults ages 25 to 34, including about 5,200 with a history of knee injuries, for almost two decades. Compared to people who never had knee injuries, those who did were nearly six times as likely to develop knee osteoarthritis during the first 11 years of follow-up, with more than triple the risk over the next eight years.

Injuries that occur inside the knee joint, for example in the meniscus or cruciate ligament, may alter the biomechanical loading patterns in the knee, said study leader Barbara Snoeker, of Lund University in Sweden.

Such injuries may lead to an imbalance in force transmissions inside the knee joint, consequently overloading the joint cartilage and leading to increased risk of developing osteoarthritis, compared to injuries that mainly affect the outside of the knee joint, such as contusions, Snoeker said by email.

Osteoarthritis often affects the large weight-bearing joints and can eventually lead to the need for total joint replacement, the researchers note in the British Journal of Sports Medicine.

Known risk factors include being overweight, older, female or having a job that puts a lot of stress on the joints, the study team notes. While a history of knee injuries is also a known risk factor, research to date hasnt offered a clear picture of whether certain types of injuries might be more likely to lead to osteoarthritis.

Two-thirds of the people in the study with knee injuries were male. After 19 years of follow-up, 422 people with knee injuries, or 11.3%, developed knee osteoarthritis. So did 2,854, or 4%, of people without knee injuries.

Most often, injuries involved multiple structures of the knee; this accounted for 21% of participant knee injuries. The second most common type of injury was cuts and contusions, at 18%, followed by cartilage or other tissue tears at 17%.

Cruciate ligament injuries, or damage to the tissue connecting the thighbone to the shinbone, were associated with a 19.6% greater risk of knee osteoarthritis, the study also found. Meniscal tears, or damage to cartilage connecting the same two bones, were associated with a 10.5% greater risk of osteoarthritis. Fractures of the shinbone where it meets the knee, or of the kneecap, were associated with a 6.6% greater risk.

Injuries involving multiple structures in the knee may have been underreported, leading researchers to underestimate the risk associated with these types of injuries, Jonas Bloch Thorlund, a professor of musculoskeletal health at the University of Southern Denmark, in Odense, who wasnt involved in the study, said by email.

Another limitation is that researchers didnt look at patients body mass index (BMI), so they couldnt tell whether differences in weight might explain patients risk of osteoarthritis, said Dr. Kyle Hammond of the Emory Sports Medicine Center in Atlanta.

What happens after knee injuries can also influence the risk of osteoarthritis down the line, Hammond, who wasnt involved in the study, said by email.

Counseling a patient on how to safely and consistently return to a positive fitness program ensures that they will maintain flexibility and strength, as well as keeping their weight at their ideal body weight, Hammond advised.

Rehab matters regardless of what other treatments patients receive, said Adam Culvenor, a sports and exercise medicine researcher at La Trobe University in Bundoora, Australia, who wasnt involved in the study.

Once these injuries occur, optimally managing them with an intense and progressive period of rehabilitation under the guidance of a physical therapist (irrespective of the decision to have surgery or not) to strengthen the muscles around the knee to facilitate a return to function and physical activity is likely to reduce the risk of osteoarthritis and persistent symptoms longer-term, Culvenor said by email.

SOURCE: bit.ly/2MhjRto British Journal of Sports Medicine, online December 11, 2019.

View post:
Knee injuries in early adulthood may hasten arthritis - Reuters

Read More...

Family Health West’s Dr.Rook Discusses Spondyloarthritis and Inflammatory Arthritis – KKCO-TV

Monday, December 23rd, 2019

FRUITA,Co.(KKCO)-- Dr.Rooks rheumatologist from the Arthritis Center of Western Colorado at Family Health West stopped by and discussed the difference between Spondyloarthritis and Inflammatory arthritis.

Doctors see a lot of patients with Spondyloarthritis on the Western slope especially among young adults.

Symptoms of Spondyloarthritis are stiffness when you wake up, and inflammation in the spine, hips, and knees.

Inflammatory arthritis is the most common type of arthritis. Symptoms include new joint or tendon pain, swelling, stiffness that lasts more than an hour in the morning without prior injury.

Inflammatory arthritis is actually a systemic disease of the immune system that, if not treated appropriately, can lead to joint and tendon damage, deformities, and contribute to heart attacks, strokes, and more.

If you have more questions on arthritis visit their website http://www.ac-wc.com.

Go here to read the rest:
Family Health West's Dr.Rook Discusses Spondyloarthritis and Inflammatory Arthritis - KKCO-TV

Read More...

Contraceptive Use in Women of Childbearing Ability With Rheumatoid Arthritis – DocWire News

Monday, December 23rd, 2019

BACKGROUND/OBJECTIVE:

Rheumatoid arthritis (RA) is a complex disease that may require treatment with one or several disease-modifying antirheumatic drugs (DMARDs). Many DMARDs have potential teratogenic effects or are newer agents with limited safety data in pregnancy. This study evaluated 20 common RA medications and the rate of contraceptive prescribing and counseling patterns in women with RA of childbearing ability.

This was an observational study of women with RA and childbearing ability aged 18 to 44 years who were seen at an academic rheumatology clinic from April 1, 2014, to March 31, 2016. Descriptive statistics and univariate logistic regression were used for analysis.

One hundred fifty women were included in the analysis. The majority of patients were taking methotrexate (55.3%), followed by chronic prednisone (31.3%) and hydroxychloroquine (28.7%). A documented method of contraception was noted in 64/150 (42.7%). For women on contraception, most used combined oral contraceptives (31/64, 48.4%) or levonorgestrel intrauterine device (10/64, 15.6%). Of the 86 patients not on contraception, 19 (22.1%) received counseling regarding a pregnancy plan.

Most women with RA of childbearing age and ability were not using contraception. Among these patients, only a minority prescribed DMARD therapy had documented pregnancy or contraceptive counseling. Women with RA who were prescribed with a DMARD should discuss the use of effective contraception with their provider if sexually active and not desiring pregnancy or wanting to avoid potential teratogenic effects. Potential strategies are discussed to improve healthcare delivery to this population in hopes of avoiding unintended pregnancy and potential teratogenic effects of RA medications.

Original post:
Contraceptive Use in Women of Childbearing Ability With Rheumatoid Arthritis - DocWire News

Read More...

Page 39«..1020..38394041..5060..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick